89Zr-AF650免疫PET成像检测胰腺癌Trop-2表达
研究以89Zr标记抗Trop-2抗体AF650,在三种胰腺癌细胞系和小鼠皮下及原位移植瘤模型中评估Trop-2免疫PET靶向能力;BxPC-3高表达Trop-2,注射后120小时瘤内摄取约28.8±7.63%ID/g,显著高于低表达模型,原位模型可清晰识别原发瘤。
要点
- 89Zr-DFO-AF650对Trop-2具有高亲和力,Kd=22.34±2.509 nM。
- BxPC-3瘤120小时摄取28.8±7.63%ID/g,远高于MIA PaCa-2和AsPC-1瘤。
- 原位BxPC-3模型中PET成像与生物分布高度相关,可识别原发瘤。
核心结论
- 89Zr-DFO-AF650可通过Trop-2介导的免疫PET在体内有效检测胰腺癌,显示Trop-2无创成像在胰腺癌检测和治疗监测中的潜力。
研究设计与样本
- 将AF650与去铁胺(DFO)偶联并用89Zr标记,在三种胰腺癌细胞系中检测Trop-2表达水平。
- 在皮下移植胰腺癌小鼠模型中行PET成像与生物分布研究,并在Trop-2阳性原位胰腺癌模型中验证靶向特异性。
主要发现
- BxPC-3细胞高表达Trop-2,AsPC-1和MIA PaCa-2细胞低表达Trop-2。
- 89Zr-DFO-AF650在BxPC-3细胞中对Trop-2显示高特异性,Kd=22.34±2.509 nM。
- 皮下移植模型中注射后120小时BxPC-3瘤摄取约28.8±7.63%ID/g,高于MIA PaCa-2瘤(6.76±2.08%ID/g)和AsPC-1瘤(3.51±0.69%ID/g)(n=4)。
- 89Zr-DFO-AF650可有效区分原位BxPC-3模型的原发瘤,PET成像与生物分布高度相关。
关键数值与推荐
- BxPC-3细胞高表达Trop-2,AsPC-1和MIA PaCa-2细胞低表达Trop-2。
- 89Zr-DFO-AF650在BxPC-3细胞中的Kd=22.34±2.509 nM。
- 注射后120小时BxPC-3瘤摄取28.8±7.63%ID/g,MIA PaCa-2瘤6.76±2.08%ID/g,AsPC-1瘤3.51±0.69%ID/g(n=4)。
临床怎么用
- Trop-2免疫PET有望用于胰腺癌的无创检测与治疗监测,但当前证据来自细胞和动物模型,尚需临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Without a standard test for pancreatic carcinomas, this highly lethal disease is normally diagnosed at its advanced stage, leading to a low survival rate of patients. Trophoblast cell-surface antigen 2 (Trop-2), a transmembrane glycoprotein, is associated with cell proliferation and highly expressed in most of solid epithelial tumors, including pancreatic cancer. A non-invasive method of imaging Trop-2 would greatly benefit clinical diagnosis and monitoring of pancreatic cancer. In the current study, 89Zr-labeled anti-Trop-2 antibody (AF650) was recruited for the systemic evaluation of Trop-2 as an immunoPET target for pancreatic cancer imaging. METHODS: AF650 was conjugated with desferrioxamine (DFO) and then radiolabeled with 89Zr. Trop-2 expression levels were determined in three pancreatic cancer cell lines (BxPC-3, MIA PaCa-2, and AsPC-1) via western blot, flow cytometry, saturation binding assay, and immunofluorescence staining. The targeting capacity of 89Zr-DFO-AF650 was evaluated in mouse models with subcutaneous xenograft of pancreatic cancers via PET imaging and bio-distribution studies. In addition, a Trop-2-positive orthotopic cancer model was recruited for further validating the targeting specificity of 89Zr-DFO-AF650. RESULTS: BxPC-3 cells expressed high levels of Trop-2, while AsPC-1 and MIA PaCa-2 cells expressed low levels of Trop-2. Additionally, 89Zr-DFO-AF650 exhibited high specificity to Trop-2 in BxPC-3 cells (Kd = 22.34 ± 2.509 nM). In subcutaneous xenograft models, about 28.8 ± 7.63%ID/g tracer accumulated in the BxPC-3 tumors at 120 h post injection, which was much higher than those reaching MIA PaCa-2 (6.76 ± 2.08%ID/g) and AsPC-1 (3.51 ± 0.69%ID/g) tumors (n = 4). More importantly, 89Zr-DFO-AF650 could efficiently distinguish primary tumors in the orthotopic BxPC-3 cancer model, showing high correlation between PET imaging and bio-distribution and sensitivity. CONCLUSIONS: 89Zr-DFO-AF650 can be effectively used to detect pancreatic cancer via Trop-2-mediated immunoPET in vivo, clearly revealing the great potential of Trop-2-based non-invasive imaging in pancreatic cancer detection and treatment monitoring.
引用
- Chen W, Li M, Younis MH, et al. ImmunoPET of trophoblast cell-surface antigen 2 (Trop-2) expression in pancreatic cancer. Eur J Nucl Med Mol Imaging. 2021. PMID: 34519889. doi:10.1007/s00259-021-05563-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。